Roche is buying Promedior to obtain its entire medical portfolio. Promedior’s leading drug candidate is designed to treat idiopathic pulmonary fibrosis, a disease for which only two drugs are approved to treat, one of which is made by Roche.
Under the deal, Roche will pay Promedior another $1 billion if its drug development program meets goals for approval and marketing, according to The Boston Globe.
Bristol-Myers Squibb had a similar deal with Promedior in 2015, but decided last year not to buy the company.
Read the full article here.
More articles on pharmacy:
Drugmakers could lose $1T in sales and still be most profitable industry, analysis finds
CAR-T costs ‘not sustainable’ for hospitals, researchers say
How Walgreens, CVS see the future of pharmacy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
